Bank of Montreal Can Purchases 2,488 Shares of ARK Genomic Revolution ETF (BATS:ARKG)

Bank of Montreal Can lifted its stake in ARK Genomic Revolution ETF (BATS:ARKG) by 39.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 8,769 shares of the company’s stock after purchasing an additional 2,488 shares during the period. Bank of Montreal Can’s holdings in ARK Genomic Revolution ETF were worth $206,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in ARKG. Hemington Wealth Management increased its stake in ARK Genomic Revolution ETF by 44.6% during the 4th quarter. Hemington Wealth Management now owns 1,310 shares of the company’s stock valued at $30,000 after purchasing an additional 404 shares in the last quarter. Union Bancaire Privee UBP SA purchased a new stake in ARK Genomic Revolution ETF during the 4th quarter valued at approximately $45,000. ARK Investment Management LLC boosted its stake in ARK Genomic Revolution ETF by 72.7% during the fourth quarter. ARK Investment Management LLC now owns 5,989 shares of the company’s stock valued at $141,000 after buying an additional 2,521 shares during the last quarter. Clientfirst Wealth Management LLC bought a new position in shares of ARK Genomic Revolution ETF in the 4th quarter valued at about $228,000. Finally, Whipplewood Advisors LLC bought a new position in ARK Genomic Revolution ETF during the fourth quarter valued at $305,000.

ARK Genomic Revolution ETF Stock Down 5.1 %

Shares of ARK Genomic Revolution ETF stock opened at $22.40 on Friday. The stock’s fifty day moving average is $22.42 and its two-hundred day moving average is $24.26. ARK Genomic Revolution ETF has a 52 week low of $17.51 and a 52 week high of $31.16.

About ARK Genomic Revolution ETF

The ARK Genomic Revolution ETF (ARKG) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund is an actively managed fund that targets companies involved in the genomics industry. ARKG was launched on Oct 31, 2014 and is managed by ARK.